Androgen receptor reverts dexamethasone-induced inhibition of prostate cancer cell proliferation and migration

JU GUO1, KE MA2, HAI-MEI XIA3, QING-KE CHEN1, LEI LI3, JUN DENG1, JING SHENG4, YAN-YAN HONG4 and JIE-PING HU1

1Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006; 2Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250355; Departments of 3Anesthesiology and 4Nursing, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China

Received October 9, 2017; Accepted December 21, 2017

DOI: 10.3892/mmr.2018.8566

Abstract. The aim of the present study was to determine the role of androgen receptor in the effect of dexamethasone on cell proliferation and migration of multiple prostate cancer cells. The prostate cancer cell lines LNCaP, 22Rv1, C4-2 and PC3 were cultured in vitro. For glucocorticoid-induced experiments, the cells were transferred and cultured in RPMI-1640 medium with 10% charcoal-stripped serum from RPMI-1640 medium with 10% fetal bovine serum for at least 24 h. The effects of dexamethasone on the proliferation and migration of various cell lines were analyzed by MTT and migration assays. Dexamethasone exhibited no effect on LNCaP, C4-2 and 22Rv1 cell lines, but suppressed proliferation of glucocorticoid receptor (GR)-androgen receptor (AR) PC3 cell line. Dexamethasone suppressed PC3 cell migration, and did not affect migration of PC3-AR9 cells. Dexamethasone positively or negatively regulated proliferation of various prostate cancer cells based on AR and GR expression profiles. The data presented in the present study indicates that androgen receptor reverts the dexamethasone-induced inhibition of prostate cancer cell proliferation and migration.

Introduction

Prostate cancer has been the most prevalent disease among men for decades and estimated 180,890 new prostate cancer cases have been diagnosed in 2016 which accounts for 21% of all cancer diagnoses that year (1). Androgen expression or androgen receptor (AR) activation serve a role in the prostate cancer (PCa) and androgen deprivation therapy (ADT) has been extensively applied as a treatment. The progress of battling PCa was made substantially based on ADT, such as combining radical radiotherapy with ADT may improve overall survival outcome in localized PCa patients (2). Following a median treatment of 24 months, almost all prostate cancer cases invariably progress to castration resistant prostate cancer (CRPC), maintaining AR activity and continuation of ADT is recommended for treatment (3,4).

In the process of ADT, adverse effects on bone, metabolic, cardiovascular, sexual and cognitive health as well as body composition are known by clinicians (5). To alleviate pain and improve the quality of life, glucocorticoids (GCs) combined with antitumor or antiandrogen agents (including Docetaxel and Abiraterone acetate) are a common class of adjuvant drugs for treatment of CRPC (6,7). Apart from ameliorating side effects caused by antitumor or antiandrogen agents, a direct effect has been identified on prostate cancer cell proliferation (8,9). GC inhibits prostate cancer cell proliferation in vivo and vitro (8,9). By contrast, an increasing amount of evidence demonstrates that glucocorticoid receptor confers resistance to antiandrogens (10,11). Therefore, GC serves a complex role in treatment, management and progression of CRPC and understanding the biological role of glucocorticoids in patients with prostate cancer is of major importance (12).

The effects of GC on prostate cancer cells, especially the castration resistance prostate cancer cells, remain to be elucidated. An association between AR and glucocorticoid receptor (GR) has been previously demonstrated and GR was negatively regulated by active androgen receptor signaling (13). Dexamethasone is a common GC agent used in the clinic (14,15). A recent study demonstrated that dexamethasone may be more effective compared with prednisolone for prostate cancer treatment (14). Therefore, the present study aimed to determine the effects of dexamethasone on prostate cancer cells. Recently, it has been demonstrated that dihydrotestosterone (DHT) can promote prostate cancer cell proliferation via glucocorticoid receptor (GR) (16). In the present study, prostate cancer cells were cultured in RPMI-1640 with 10% charcoal-stripped serum to investigate the effects of dexamethasone on prostate cancer cell proliferation and migration ability, and the role of AR in the effects.

Correspondence to: Dr Jie-Ping Hu, Department of Urology, The First Affiliated Hospital of Nanchang University, 17 Yongwai Zheng Road, Nanchang, Jiangxi 330006, P.R. China
E-mail: hu_jieping@163.com

Key words: prostate cancer, androgen receptor, glucocorticoid receptor, proliferation, migration
Materials and methods

Cell culture. Human PCa cell lines, PC3-AR9 was provided as a gift from professor Niu (Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin, China) (17), LNCaP, CWR22Rv1, C4-2, Du145 and PC3 (American Type Culture Collection; Manassas, VA, USA) were routinely maintained in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 10% FBS (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 100 U/ml of penicillin and 100 mg/ml of streptomycin in a 5% CO₂ atmosphere at 37°C. For glucocorticoid-induced experiments, the cells were transferred and cultured in RPMI-1640 with 10% charcoal-stripped serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) for 24 h in a 5% CO₂ atmosphere at 37°C. The charcoal-stripped serum contains reduced hormone levels and is suitable for AR or GR signaling studies. DHT (MedChemExpress Co., Ltd., Princeton, New Jersey, USA) was dissolved in ethanol in 10⁻⁴ M concentration, DHT was diluted 1,000-fold in RPMI-1640 (Invitrogen; Thermo Fisher Scientific, Inc.) with 10% charcoal-stripped serum (HyClone; GE Healthcare Life Sciences) to reach a final concentration of 10 nM. Dexamethasone was dissolved in DMSO at 2x10⁻⁴ M final concentration, which was further diluted 100,000-fold in the RPMI-1640 medium with 10% charcoal-stripped serum to reach a final concentration of 100 nM.

Measurement of cell viability. Cell viability was assessed by MTT assay. MTT assay was modified (150 µl DMSO were used and a microplate reader at a wavelength of 490 nm instead of 50 µl DMSO at 570 nm) and performed to quantify cell proliferation (18). Briefly, LNCaP (3x10⁴), C4-2 (10⁴), 22Rv1 (10⁴), PC-3 (10⁴), Du145 (10⁴) and PC3-AR9 (3x10⁴). Cells were maintained in RPMI-1640 medium (Invitrogen; Thermo Fisher Scientific, Inc.) with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.) and were incubated in 96-well microplates with RPMI-1640 medium supplemented with 10% charcoal-stripped serum medium. Following 24 h, the medium was removed and replaced by either a medium containing different concentration of drug (RPMI-1640 medium supplemented with 10% charcoal-stripped serum with 10-8 M DHT, 10 nM dexamethasone, or 10 uM MDV3100; Selleck Chemicals, Shanghai, China) or a drug-free medium (control condition: DMSO or ethanol diluted in RPMI-1640 medium supplemented with 10% charcoal-stripped serum). Following 24, 48, 72 and 96 h or on day 2, 4 and 6 the media were removed and replaced with 100 µl of 1 mg/ml MTT (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) in RPMI-1640. Following a 4-h incubation in a 5% CO₂ atmosphere at 37°C, the MTT solution was removed and replaced with 150 µl DMSO, and the plates were shaken for 3 min on an oscillator. The optical density of each sample was determined using a microplate reader at a wavelength of 490 nm. Each experiment was performed in triplicate.

Western blot analysis. Harvested cells following the aforementioned treatment, were washed with PBS and lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 150 mM NaCl; 1 mM EDTA; 1 mM proteinase inhibitor; 1 mM Na₃VO₄; 1 mM NaF; 1 mM okadaic acid; and 1 mg/ml aprotinin, leupeptin and pepstatin). Cytoplasmic and nuclear extracts were prepared as previously described (19). Prior to the procedure, the following compounds were prepared: Buffer A: 10 mM HEPES (Sigma-Aldrich; Merck KGaA), pH 7.9, 1.5 mM MgCl₂ (Sigma-Aldrich; Merck KGaA), 10 mM KCl (Sigma-Aldrich; Merck KGaA), 300 mM sucrose (Sigma-Aldrich; Merck KGaA), 0.5% NP-40 (Sigma-Aldrich; Merck KGaA), stored at 4°C; Buffer B: 20 mM HEPES, pH 7.9, 1.5 mM MgCl₂, 420 mM NaCl (Sigma-Aldrich; Merck KGaA), 0.2 mM EDTA (Invitrogen; Thermo Fisher Scientific, Inc.), 2.5% glycerol (Sigma-Aldrich; Merck KGaA), stored at 4°C; and Buffer D: 20 mM HEPES, pH 7.9, 100 mM KCl, 0.2 mM EDTA, 8% glycerol, stored at 4°C. Medium was removed from the cultures and cells were washed in cold PBS, and harvested with a rubber scraper. Subsequently, cells were centrifuged at 550 x g for 5 min at 4°C and supernatant was discarded. The following inhibitors were added to buffers A, B and D: 0.5 mM PMSF (Sigma-Aldrich; Merck KGaA), 1 mM Na₃VO₄ (Sigma-Aldrich; Merck KGaA), 0.5 mM DTT (Invitrogen; Thermo Fisher Scientific, Inc.), 1 µg/ml leupeptin (Sigma-Aldrich; Merck KGaA), 25 mM β-glycerophosphate (Sigma-Aldrich; Merck KGaA), 10 mM NaF (Sigma-Aldrich; Merck KGaA). The pellet was resuspended in 2X cell volume of buffer A with inhibitors and the solution was kept on ice for 10 min. Samples were vortexed briefly and centrifuged at 2,600 x g for 30 sec at 4°C. The supernatant was collected which corresponds to cytoplasm proteins. The pellet was resuspended in buffer B with inhibitors. The mixture was sonicated for 5 sec at 4°C and centrifuge at 10,400 x g for 5 min at 4°C. The supernatant was diluted with equal volume of buffer D with inhibitors, and nuclear protein was extracted. Protein concentration was measured by coomassie brilliant blue. Samples (30 µg protein/lane) were separated on 8% SDS-PAGE gel and transferred to polyvinylidene fluoride membranes at 4°C (250 mA, 2 h). Membranes were blocked in 5% fat-free milk in TBS with 1% Tween-20 for 1 h at room temperature and incubated with primary antibodies: Anti-GAPDH (Sanjan, Tianjin, China; cat. no. KM9002; 1:5,000; www.sungenebiotech.com), anti-GR (BIOS, Beijing, China; cat. no. bs-0252R; 1:500), anti-Histone3 (used as nuclear control; Abcam, Cambridge, UK; cat. no. ab8580; 1:1,000), AR (Abcam; cat. no. ab9474; 1:1,000), Akt (Abcam; cat. no. ab8805; 1:1,000), p-Akt (Abcam; cat. no. ab18283; 1:1,000), vimentin (Abcam; cat. no. ab92547; 1:1,000) overnight at 4°C. Subsequently, the membranes were washed in TBS with 1% Tween (TBST) for 10 min/wash 3 times and incubated with horseradish peroxidase conjugated anti-rabbit or anti-mouse antibodies (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA; cat. no.) for 1 h at room temperature and washed for 10 min/wash 3 times. The blots were developed in Enhanced Chemiluminescence mixture (Amersham Biosciences; GE Healthcare, Chicago, IL, USA) and visualized by Imager (Image J, National Institutes of Health, version 1.48).

Migration assay. Cells (10⁵ of PC3-AR9 and 5x10⁴ of PC3) following different treatments (DMSO or dexamethasone) were re-suspended with RPMI-1640 with 10% charcoal-stripped serum (HyClone; GE Healthcare Life Sciences, Logan, UT, USA) and seeded in the upper chambers of the transwells (Corning Inc., Corning, NY, USA). A 10% solution
of FBS (Gibco; Thermo Fisher Scientific, Inc.) with or without 100 nM dexamethasone was applied in the lower chamber. As described previously (17), following a 24- or 48-h incubation (with PC3 or PC3-AR9 cells, respectively), the cells that invaded to the lower part of the membrane were harvested, fixed with 75% ethanol and stained with 0.1% crystal violet at room temperature for 25 min in PBS. Invaded cells were counted under a light microscope (magnification, x100). The standard deviation was calculated from three independent wells.

**Statistical analysis.** All values are presented as the mean ± standard error of the mean. Statistical evaluation of the results was performed by one-way analysis of variance followed by the Newman-Keuls method (SPSS software; version 18.0; SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**Dexamethasone affects prostate cancer cell proliferation.** Glucocorticoids exert effects through non-genomic action or genomic action mediated by GR (15,20). To investigate the effects of glucocorticoids on prostate cancer cells, GR expression was initially assessed in various cell lines. PC3 and Du145 demonstrated elevated GR expression compared with other cells, whereas no AR expression was detected in these cells (Fig. 1A). AR was expressed in LNCaP, C4-2 and 22Rv1 cells, whereas GR expression was low or hardly detectable in these cells. Dexamethasone was used to treat the cell lines in the present study. Dexamethasone treatment inhibited the PC3 and Du145 cell proliferation (Fig. 1B and C), but exerted no effect on proliferation of (D) LNCaP, (E) C4-2 and (F) 22Rv1. Dex, dexamethasone; AR, androgen receptor; GR, glucocorticoid receptor. Data are presented as the mean ± standard deviation. ***P<0.001.

**AR reverts the inhibition of dexamethasone on prostate cancer cell proliferation.** To determine the role of AR in the effect of dexamethasone on prostate cancer cell proliferation, PC3 cells were transfected with AR in to establish a PC3-AR9 cell line, as previously described (21). The transfected cell line expressed both AR and GR (Fig. 2A). By contrast to the PC3 cells, dexamethasone exerted positive effect on PC3-AR9 cell proliferation (Fig. 2B). This effect was not affected by AR agonist DHT (Fig. 2C) or antagonist MDV3100 (Fig. 2D). Therefore, AR reverted the inhibition of dexamethasone on
GUO et al: THE FUNCTIONS OF DEXAMETHASONE IN PROSTATE CANCER CELLS

Prostate cancer cell proliferation. The treatment with an agonist and antagonist indicated that this alteration was depended on AR protein but not AR signal.

Phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K)-RAC-alpha serine/threonine-protein kinase (Akt) pathway is involved in the distinct effect of dexamethasone on various prostate cancer cells. It has been previously demonstrated that AR expression and translocation influence prostate cancer cell proliferation (22). AR expression and distribution were investigated upon dexamethasone treatment; however, AR expression was not significantly affected by dexamethasone treatment (Fig. 3A) and no AR protein was detected in the nuclei (Fig. 3B). A direct interaction between Akt and AR was previously demonstrated by co-immunoprecipitation, and increased phosphorylation of Akt (Ser-473 and Thr-308) was associated with phosphorylation at Ser213 and Ser791, and AR degradation (22). The present study demonstrated that p-Akt\textsuperscript{473} increased following dexamethasone treatment in PC3 cells, but decreased in PC3-AR9 cells (Fig. 3C). p-Akt\textsuperscript{473} level was unaltered despite dexamethasone treatment in 22Rv1 and C4-2 cells (Fig. 3D). The present data are consistent with a previous study where Akt-AR interaction in androgen dependent prostate cancer (ADPC) and androgen independent prostate cancer (AIPC) was different (23).

AR rescues the inhibition of dexamethasone on prostate cancer migration. To assess the effect of dexamethasone on prostate cancer migration, a migration assay was performed using PC3 cells. Dexamethasone inhibited cell migration in PC3 cells (Fig. 4A and B). However, dexamethasone exhibited no influence on PC3-AR9 cell migration ability (Fig. 4C and D). Therefore, AR rescued the inhibition of dexamethasone on prostate cancer migration. The expression of mesenchymal marker vimentin was decreased following dexamethasone treatment in PC3 cells and unaltered in PC3-AR9 cells (Fig. 4E), which may indicate that dexamethasone may be linked with epithelial mesenchymal transition (EMT) and AR may alter dexamethasone’s effect.

Discussion

It has been previously hypothesized that dexamethasone may inhibit prostate cancer proliferation and that the underlying mechanisms may involve interleukin (IL)-6, nuclear factor-κB inhibition (8,24). A previous study suggested that glucocorticoids exhibit a distinct effect on prostate cancer cells, suppress PC3 and Du145 cell proliferation and induce no effect on LNCaP cells (8). Glucocorticoids can also promote prostate cancer cell proliferation and previous data demonstrated that dexamethasone promotes proliferation of 22Rv1 cells (11,25). Recently published data indicated that DHT can affect AR-prostate cancer cell proliferation via GR (16). Therefore, the authors of the present study evaluated dexamethasone action in the absence of androgen.

In the present study, it was demonstrated that dexamethasone exhibits different action on LNCaP, PC3, 22Rv1 and C4-2 cells. Dexamethasone inhibited PC3 proliferation but did not affect the proliferation of LNCaP, 22Rv1, C4-2 cells. Dexamethasone inhibited PC3 proliferation but did not affect the proliferation of LNCaP, 22Rv1, C4-2 cells. Dexamethasone inhibited PC3 proliferation but did not affect the proliferation of LNCaP, 22Rv1, C4-2 cells.
study hypothesized that the action of dexamethasone on prostate cancer cells may depend on the presence of AR. Dexamethasone promoted cancer cell proliferation in PC3 cells transfected with AR (Fig. 2B).

The present study investigated the effect of dexamethasone on various prostate cancer cells. The association between AR and GR is complex and their interaction is influenced by disease progression (12). The expression of GR is negatively regulated by active androgen receptor signaling (13). By contrast, androgen receptor activity was inhibited by glucocorticoid action in human adipocytes (26). Whether androgen receptor activity was inhibited by glucocorticoid action has not been fully demonstrated in prostate cancer cells (12). Nevertheless, the immunophilin FKBP51 which is the downstream of AR regulates the function of GR (26,27). Increased expression of FKBP51 by AR inhibits GR nuclear translocation and therefore suppresses the function of GR (27,28). Therefore, prostate cancer cells should be divided into four types according to AR and GR expression (double AR/GR+ or − and AR/GR single positive).

Figure 3. Akt pathway is involved in the distinct effect of dexamethasone on prostate cancer cells. (A) Western blotting indicated that dexamethasone exhibited no influence on AR expression in PC3-AR9 cells. (B) AR nucleus-cytoplasm distribution was not affected by dexamethasone. Dexamethasone (C) promoted Akt phosphorylation in PC3 cells and inhibited Akt phosphorylation in PC3-AR9, and (D) exhibited no effect on 22Rv1 or C4-2 cells. Akt, RAC-alpha serine/threonine-protein kinase; p, phosphorylated; AR, androgen receptor; dex, dexamethasone. Data are presented as the mean ± standard deviation. **P<0.01, ***P<0.001.

Figure 4. AR rescues the inhibition induced by dexamethasone on prostate cancer migration. Migration assay indicated that dexamethasone (A) inhibited PC3 cell migration, (B) as demonstrated by quantitative analysis, but (C) exhibited no effect on PC3-AR9 cell migration, (D) as demonstrated by quantitative analysis. (E) Western blotting indicated that dexamethasone inhibited vimentin expression in PC3 cells but not in PC3-AR9 cells. Data are presented as the mean ± standard deviation. *P<0.05, **P<0.001.
Clinically, multiple studies investigated the utility of dexamethasone in CRPC (14,29-34). Prostate-specific antigen (PSA) response rate of dexamethasone is ~41-62%, median time to PSA progression of dexamethasone is ~5.4-9.7 months. Dexamethasone induces distinct effect in various clinical studies (reviewed in 15). In order to confirm the present findings, future in vivo experiments and experiments using more cell lines are needed.

When PCA is a localized disease, five year survival rates can be 100% but once it has spread, the survival rates decrease to 28% (35). Cancer metastases markedly decrease patients' survival time. The present study performed a migration assay to determine the effects of dexamethasone on prostate cancer migration. Dexamethasone inhibited PC3 cell migration but did not affect PC3-AR9 cell migration. In bladder cancer, dexamethasone increased glucocorticoid receptor-mediated reporter activity and cell proliferation; however, dexamethasone induced mesenchymal-to-epithelial transition by suppressing the expression of MMP-2/MMP-9, IL-6, VEGF, and the activity of MMP-2/MMP-9, thus inhibited bladder cell invasion (36). Although the mechanism of dexamethasone activity on PC3 migration remains to be elucidated, it appears that dexamethasone inhibited cell migration of AR but not AR- cancer cells. As demonstrated in previous studies, dexamethasone was sufficient to confer enzalutamide resistance, and substituted for AR to activate genes involved in proliferation.

In conclusion, the present study suggested that dexamethasone positively or negatively regulated proliferation of various prostate cancer cells according to AR and GR expression.

Acknowledgements

The present study was supported by the Project of the Education Department of Jiangxi Province (grant no. GJJ160036).

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin 66: 7-30, 2016.
2. Attard G, Parker C, Ecles RA, Schröder F, Tomlins SA, Tannock I, Drake CG and de Bono JS: Prostate cancer. Lancet 387: 70-82, 2016.
3. Penner S, Cronauer MW, Schrader AJ, Klocker H, Cugil Z and Baniahmad A: Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer. Oncotarget 6: 35542-35555, 2015.
4. Saad F and Fizzi Z: Androgen deprivation therapy and secondary targeting in the management of hormone-sensitive and castration-resistant prostate cancer. Urology 86: 852-861, 2015.
5. Nguyen PL, Alihata SM, Barziza S, D’Amico AV, Kantoff PW, Keady NL, Penso DF, Rosario DJ, Tombal B and Smith MR: Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67: 825-836, 2015.
6. Tajagawa ST, Posadas EM, Bruce J, Lim EA, Petrylak DP, Peng W, Kheoh T, Maul S, Smit JW, Gonzalez MD, et al: Phase IIb study of abiraterone acetate plus prednisone and docetaxel in patients with metastatic castration-resistant prostate cancer. Eur Urol 70: 718-721, 2016.
7. Tepley BA, Luber B, Denmeade SR and Antonarakis ES: The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 19: 72-76, 2016.
8. Nishimura K, Nonomura N, Sato H, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shim M, et al: Potential mechanisms for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 93: 1739-1746, 2001.
9. Yemelyanov A, Czworog J, Chebotaev D, Karseladze A, Kulevitch E, Yang X and Budunova I: Tumor suppressor activity of glucocorticoid receptor in the prostate. Oncogene 26: 1885-1896, 2007.
10. Arora VK, Schenkein E, Murrali R, Subudhi SK, Wongvipat J, Balbas MD, Shah N, Cai L, Efstathiou E, Logothetis C, et al: Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 155: 1309-1322, 2013.
11. Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD and Szulewitz EZ: Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer 5: 72-89, 2014.
12. Narayanan S, Srivivas S, Feldman D: Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol 13: 47-60, 2016.
13. Xie N, Cheng H, Lin D, Liu L, Yang Q, Jia L, Fazli L, Gleave ME, Wang Y, Rennie P and Dong X: The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors. Int J Cancer 136: E27-E38, 2015.
14. Venkitaraman R, Lorente D, Murthy V, Thomas K, Parker L, Ahiabor R, Dearnaley D, Huddart R, De Bono J and Parker C: A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. Eur Urol 67: 673-679, 2015.
15. Hu J and Chen Q: The role of glucocorticoid receptor in prostate cancer progression: From bench to bedside. Int Urol Nephrol 49: 369-380, 2017.
16. Song C, Kim Y, Min GE and Ahn H: Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway. Prostate 74: 1240-1248, 2014.
17. Wen S, Shang Z, Zhu S, Chang C and Niu Y: Androgen receptor enhances entosis, a non-apoptotic cell death, through modulation of Rho/ROCK pathway in prostate cancer cells. Prostate 73: 1306-1315, 2013.
18. Kan SF, Huang WJ, Lin LC and Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 110: 641-651, 2004.
19. Wang J, Jiang T, Li Y, Zhang Z and Zhao H: Dihydrotestosterone enhances castration-resistant prostate cancer cell proliferation through STAT5 activation via glucocorticoid receptor pathway. Prostate 74: 1240-1248, 2014.
20. Kan SF, Huang WJ, Lin LC and Wang PS: Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 110: 641-651, 2004.
21. Wu KK: Analysis of protein-DNA binding by streptavidin–agarose pulldown. Methods Mol Biol 338: 281-290, 2006.
22. Ramamorthy S and Cidlowski JA: Exploring the molecular mechanisms of glucocorticoid receptor action from sensitivity to resistance. Endocr Dev 24: 41-56, 2013.
23. Yuan S, Trachtenberg J, Mills GB, Brown T, Xu F and Keating A: Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 53: 1304-1311, 1993.
24. Hu J, Wang G and Sun T: Dissecting the roles of the androgen receptor in prostate cancer from molecular perspectives. Tumour Biol 39: 1010428317692259, 2017.
25. Palouras M and Diamandis EP: An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines. Biol Chem 389: 773-780, 2008.
26. Yano A, Fujii Y, Iwai A, Kageyama Y and Kihara K: Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells. Clin Cancer Res 12: 3003-3009, 2006.
25. Attardi BJ, Burgenson J, Hild SA and Reel JR: Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Mol Cell Endocrinol 222: 121-132, 2004.

26. Hartig SM, He B, Newberg JY, Ochsner SA, Loose DS, Lanz RB, McKenna NJ, Bucher BM, McGuire SE, Marcelli M and Mancini MA: Feed-forward inhibition of androgen receptor activity by glucocorticoid action in human adipocytes. Chem Biol 19: 1126-1141, 2012.

27. Stechschulte LA and Sanchez ER: FKBP51—a selective modulator of glucocorticoid and androgen sensitivity. Curr Opin Pharmacol 11: 332-337, 2011.

28. Jääskeläinen T, Makkonen H and Palvimo JJ: Steroid up-regulation of FKBP51 and its role in hormone signaling. Curr Opin Pharmacol 11: 326-331, 2011.

29. Storlic JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC and Richardson RL: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 76: 96-100, 1995.

30. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T and Okuyama A: Low doses of oral dexamethasone for hormone-refractory prostate cancer. Cancer 89: 2570-2576, 2000.

31. Morioka M, Kobayashi T, Furukawa Y, Jo Y, Shinkai M, Matsui T, Yamamoto T and Tanaka H: Prostate-specific antigen levels and prognosis in patients with hormone-refractory prostate cancer treated with low-dose dexamethasone. Urol Int 68: 10-15, 2002.

32. Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP and Parker CC: Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 101: 440-443, 2008.

33. Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Nishimatsu H, Ishikawa A and Homma Y: Docetaxel as a vital option for corticosteroid-refractory prostate cancer. Int Urol Nephrol 43: 1081-1087, 2011.

34. Shamash J, Powies T, Sarker SJ, Protheroe A, Mithal N, Mills R, Beard R, Wilson P, Tranter N, O'Brien N, et al: A multi-centre randomised phase III trial of dexamethasone vs dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred diethylstilbestrol. Br J Cancer 104: 620-628, 2011.

35. Hodson R: Small organ, big reach. Nature 528: S118-S119, 2015.

36. Zheng Y, Izumi K, Li Y, Ishiguro H and Miyamoto H: Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals. Mol Cancer Ther 11: 2621-2632, 2012.